Literature DB >> 16467444

Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies.

Marian C Roos-van Groningen1, Eduard M Scholten, Patrick M Lelieveld, Ajda T Rowshani, Hans J Baelde, Ingeborg M Bajema, Sandrine Florquin, Frederike J Bemelman, Emile de Heer, Johan W de Fijter, Jan A Bruijn, Michael Eikmans.   

Abstract

The calcineurin inhibitor cyclosporine (CsA) induces a fibrogenic response that may lead to scarring of the renal allograft. This study investigated whether tacrolimus, a novel calcineurin inhibitor, exerts fibrogenic effects to a similar extent. Sixty patients were enrolled in a randomized study: 29 received CsA, and 31 received tacrolimus. Patients were subjected to tailored exposure-controlled calcineurin inhibitor regimens. Protocol biopsies were obtained at the time of transplantation and 6 and 12 mo after transplantation. Cortical TGF-beta and collagens alpha1(I) and alpha1(III) mRNA steady-state levels were determined with real-time PCR. The extent of protein deposition of TGF-beta, alpha-smooth muscle actin, and interstitial collagens in the renal cortex was quantified with computer-assisted image analysis. The extent of interstitial collagen deposition measured with Sirius red and the accumulation of alpha-smooth muscle actin and TGF-beta protein after 6 and 12 mo were similar for both immunosuppressive regimens. mRNA levels of TGF-beta and collagens alpha1(I) and alpha1(III) were not significantly different in the treatment groups either. It is concluded that the fibrogenic response in renal allografts is similar in patients who receive CsA-based regimens and patients who receive tacrolimus-based regimens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467444     DOI: 10.1681/ASN.2005080891

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  21 in total

Review 1.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 2.  Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation.

Authors:  Adnan Sharif; Shazia Shabir; Sourabh Chand; Paul Cockwell; Simon Ball; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2011-09-23       Impact factor: 10.121

Review 3.  Calcineurin inhibitors and nephrotoxicity in children.

Authors:  Fei Liu; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2018-03-12       Impact factor: 2.764

Review 4.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

5.  Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study.

Authors:  Marlies E J Reinders; Johan W de Fijter; Helene Roelofs; Ingeborg M Bajema; Dorottya K de Vries; Alexander F Schaapherder; Frans H J Claas; Paula P M C van Miert; Dave L Roelen; Cees van Kooten; Willem E Fibbe; Ton J Rabelink
Journal:  Stem Cells Transl Med       Date:  2013-01-24       Impact factor: 6.940

6.  Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.

Authors:  Jing-Cheng Hao; Wen-Tao Wang; Lu-Nan Yan; Bo Li; Tian-Fu Wen; Jia-Yin Yang; Ming-Qing Xu; Ji-Chun Zhao; Yong-Gang Wei
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 7.  Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.

Authors:  Andrew Scott Mathis; Gwen Egloff; Hoytin Lee Ghin
Journal:  World J Transplant       Date:  2014-06-24

8.  Early epithelial phenotypic changes predict graft fibrosis.

Authors:  Alexandre Hertig; Dany Anglicheau; Jérôme Verine; Nicolas Pallet; Maxime Touzot; Pierre-Yves Ancel; Laurent Mesnard; Nicole Brousse; Edith Baugey; Denis Glotz; Christophe Legendre; Eric Rondeau; Yi-Chun Xu-Dubois
Journal:  J Am Soc Nephrol       Date:  2008-04-23       Impact factor: 10.121

Review 9.  Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result.

Authors:  Titte R Srinivas; Herwig-Ulf Meier-Kriesche
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

10.  Urinary vitronectin identifies patients with high levels of fibrosis in kidney grafts.

Authors:  Laura Carreras-Planella; David Cucchiari; Laura Cañas; Javier Juega; Marcella Franquesa; Josep Bonet; Ignacio Revuelta; Fritz Diekmann; Omar Taco; Ricardo Lauzurica; Francesc Enric Borràs
Journal:  J Nephrol       Date:  2020-12-04       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.